The pharmaceutical industry has traditionally focused on developing therapies using synthetic small molecules. However many environments such as a generic threat and an R&D productivity crisis have changed the dynamics of the pharmaceutical industry. The major players in the industry have recognized the high potential of biological therapies. In near future, it is expected to drive a significant change in their R&D portfolios. Biologics are expected to account for the majority of the total growth in the pharmaceutical sector. In 2014, seven among the top 10 products by sales will be the Biologics. One of the major fields for application of biological products is the autoimmune disease such as a Rheumatoid arthritis. The market size of the TNF blockade will be expended to 20 billion dollars. The final goal of our program is to commercialize the biologics as a best in class drug and/or as a first in class drug for the treatment of autoimmune diseases.
한국생물공학회 [The Korean Society for Biotechnology and Bioengineering]
설립연도
1984
분야
공학>생물공학
소개
이 법인은 생물 공학의 발전과 보급에 이바지하고, 회원 상호 간의 연구 협력과 친목을 도모함을 목적으로 한다
1. 생물공학 분야의 발전을 위한 연구 협력
2. 생물공학의 실용화를 촉진시키기 위한 산학 협동
3. 학술연구 발표회, 강연회, 연수회 등 학술활동의 개최
4. 국,영문 학술지,소식지,학술회의 Proceedings 및 학술도서의 발간
5. 생물공학 발전을 위한 정책 건의
6. 기타 국제 교류 등 본 학회의 목적 달성을 위한 제반 활동